Printer manufacturer Seiko Instruments has released a new lineof dye sublimation printers that add support for the PostScriptprinting protocol. Seiko hopes that the 8.5 x 11 version of theprinter line will help solidify its position in the nuclear
Printer manufacturer Seiko Instruments has released a new lineof dye sublimation printers that add support for the PostScriptprinting protocol. Seiko hopes that the 8.5 x 11 version of theprinter line will help solidify its position in the nuclear medicinemarket, where it holds a 56% market share for 8.5 x 11 printers,according to the firm.
The new printers are ColorPoint 820 PS for 8.5 x 11 printsand ColorPoint 830 PS for 11 x 17 images. The printers have anAdobe PostScript Level 2 interpreter embedded in them that enablesthem to support PostScript, according to Craig Lynar, directorof marketing for Seiko's color graphics group in San Jose, CA.
Many medical imaging vendors now format their images in PostScriptdue to the image quality advantages the protocol confers overstandard screen-capture video, Lynar said. Seiko plans to adda DICOM-compatible version to the line later this year. Seikowill continue to offer its Professional ColorPoint 2 VSF printerfor video-capture printing (SCAN 3/16/94).
Both new printers output at 300 dpi and support thermal waxtransfer printing as well as dye sublimation. Cost per letter-sizeprint is 50¢ in thermal wax mode and $2.30 in the higherresolution dye sublimation mode. Seiko has added seven new imagesmoothing algorithms to the printers to remove pixelation artifactsand make images easier to read.
Seiko will target the printers at the nuclear medicine, radiationtherapy, MRI, and CT markets. In nuclear medicine, Seiko's OEMpartners include GE, Siemens, ADAC, Toshiba, and Elscint. ColorPoint820 PS will carry a list price of $7999 while ColorPoint 830 PSis listed at $14,999.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.